BRPI0814876A2 - Análogos de pirona fosforilados e métodos - Google Patents

Análogos de pirona fosforilados e métodos

Info

Publication number
BRPI0814876A2
BRPI0814876A2 BRPI0814876-7A2A BRPI0814876A BRPI0814876A2 BR PI0814876 A2 BRPI0814876 A2 BR PI0814876A2 BR PI0814876 A BRPI0814876 A BR PI0814876A BR PI0814876 A2 BRPI0814876 A2 BR PI0814876A2
Authority
BR
Brazil
Prior art keywords
pyrona
phosphorilated
analogs
methods
pyrona analogs
Prior art date
Application number
BRPI0814876-7A2A
Other languages
English (en)
Inventor
Wendye Robbins
Ving Lee
Original Assignee
Limerick Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Limerick Biopharma Inc filed Critical Limerick Biopharma Inc
Publication of BRPI0814876A2 publication Critical patent/BRPI0814876A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0814876-7A2A 2007-07-31 2008-07-30 Análogos de pirona fosforilados e métodos BRPI0814876A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95318807P 2007-07-31 2007-07-31
US7660808P 2008-06-27 2008-06-27
PCT/US2008/071588 WO2009018338A2 (en) 2007-07-31 2008-07-30 Phosphorylated pyrone analogs and methods

Publications (1)

Publication Number Publication Date
BRPI0814876A2 true BRPI0814876A2 (pt) 2014-09-30

Family

ID=40305253

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814876-7A2A BRPI0814876A2 (pt) 2007-07-31 2008-07-30 Análogos de pirona fosforilados e métodos

Country Status (13)

Country Link
US (3) US7947733B2 (pt)
EP (1) EP2182957A4 (pt)
JP (1) JP2011500512A (pt)
KR (1) KR20100051829A (pt)
CN (1) CN101969959A (pt)
AU (1) AU2008282261A1 (pt)
BR (1) BRPI0814876A2 (pt)
CA (1) CA2693338A1 (pt)
GB (1) GB2464645B (pt)
MX (1) MX2010001141A (pt)
TW (1) TW200924785A (pt)
WO (1) WO2009018338A2 (pt)
ZA (1) ZA201001390B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090258939A1 (en) * 2007-07-31 2009-10-15 Wendye Robbins Pyrone analog compositions and methods
CA2693338A1 (en) 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Phosphorylated pyrone analogs and methods
CA2740003A1 (en) * 2008-10-10 2010-04-15 Limerick Biopharma, Inc. Pyrone analogs for therapeutic treatment
EP2424541A2 (en) * 2009-04-27 2012-03-07 Limerick BioPharma, Inc. Phosphorylated and phosphonated pyrone analogs for therapeutic treatment
JP2013527159A (ja) * 2010-04-23 2013-06-27 キネタ・インコーポレイテツド 抗ウイルス性化合物
WO2012068539A1 (en) * 2010-11-19 2012-05-24 Limerick Biopharma, Inc. Use and composition of quercetin-3'-o-sulfate for therapeutic treatment
EP2678019A4 (en) 2011-02-25 2015-05-13 Kineta Inc METHOD AND CELLS FOR IDENTIFYING RIG-I PATH REGULATORS
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN104530127B (zh) * 2014-12-12 2016-09-14 广东东阳光药业有限公司 一种淫羊藿苷衍生物及其使用方法和用途
CN106632479B (zh) * 2016-12-22 2018-10-23 贵州大学 O,o’-二烷基-o”-(取代黄酮-3-基)磷酸酯类衍生物、制备方法及应用
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US10881634B2 (en) * 2017-12-07 2021-01-05 Hughes Biotechnology Co., Ltd Method for treatment or prevention of a disease associated with a decrease in bone mass and method of improving bone architecture and bio mechanical strength of bone
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR837588A (fr) 1938-03-25 1939-02-14 Perfectionnements aux chaînes ou garnitures anti-patinantes et anti-dérapantes pour roues de véhicules
US2764596A (en) * 1952-07-01 1956-09-25 Nat Drug Co Inorganic acid esters of polyhydroxylated flavones and flavanones
US4530844A (en) * 1984-07-26 1985-07-23 Warner-Lambert Company Synergistic non-steroidal anti-inflammatory compounds and compositions thereof
JPH01153695A (ja) * 1987-12-11 1989-06-15 Showa Denko Kk ルチンまたはケルセチンリン酸エステルの製造法
JPH01308476A (ja) 1988-06-06 1989-12-13 Showa Denko Kk 紫外線吸収剤
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US5643901A (en) * 1990-06-11 1997-07-01 Fujisawa Pharmaceutical Co., Ltd. Medicament for treating idiopathic thrombocytopenic purpura
US5348966A (en) * 1990-10-24 1994-09-20 Fujisawa Pharmaceutical Co., Ltd. Method for treating pyoderma and Sezary's syndrome using FK 506 and related compounds
US5817333A (en) * 1991-10-31 1998-10-06 Fujisawa Pharmaceutical Co., Ltd. Liposome preparation containing a tricyclic compound
CA2122641A1 (en) 1991-11-18 1993-05-27 A. Stanley Tyms Phosphorylated flavanoids in the treatment of viral diseases
JPH072826A (ja) 1992-03-12 1995-01-06 Sanwa Kagaku Kenkyusho Co Ltd フラボン誘導体
US5972598A (en) * 1992-09-17 1999-10-26 Board Of Trustess Of The University Of Illinois Methods for preventing multidrug resistance in cancer cells
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
US6362160B1 (en) * 1993-06-30 2002-03-26 The Johns Hopkins University School Of Medicine Immunophilin-binding agents prevent glutamate neurotoxicity associated with vascular stroke and neurodegenerative diseases
US6022852A (en) * 1993-10-22 2000-02-08 Hexal Ag Pharmaceutical composition containing cyclosporin A
WO1996021440A1 (en) 1995-01-09 1996-07-18 Alpha-Therapeutics, Inc. Methods for increasing the bioavailability of biological active agents
ES2248847T3 (es) * 1996-05-24 2006-03-16 Angiotech Pharmaceuticals, Inc. Composiciones y metodos para tratar o prevenir enfermedades de las vias de conduccion del cuerpo.
GB9613455D0 (en) * 1996-06-27 1996-08-28 Aston Molecules Ltd Analogues or derivatives of quercetin
AU748334B2 (en) * 1997-10-16 2002-05-30 Board Of Regents, The University Of Texas System Models and treatments for cardiac hypertrophy in relation with NF-AT3 function
US6013621A (en) * 1997-10-17 2000-01-11 The Rockfeller University Method of treating psychosis and/or hyperactivity
KR20010032303A (ko) 1997-12-03 2001-04-16 후지야마 아키라 연질 펠렛상 약제 및 그 제조방법
ATE238792T1 (de) * 1998-02-23 2003-05-15 Fujisawa Pharmaceutical Co Verwendung von makroliden zur behandlung von glaukom
AUPP223198A0 (en) * 1998-03-06 1998-04-02 Fujisawa Pharmaceutical Co., Ltd. New use
US6458777B1 (en) * 1998-03-13 2002-10-01 Mucosal Therapeutics Llc Methods and compositions for treating and preventing mucositis
PT2198858E (pt) * 1998-03-26 2011-09-01 Astellas Pharma Inc Composição farmacêutica de libertação constante que contém um macrólido como o tacrolimus
WO1999051215A2 (en) * 1998-04-06 1999-10-14 Fujisawa Pharmaceutical Co., Ltd. Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins
GB9814640D0 (en) 1998-07-06 1998-09-02 Fujisawa Pharmaceutical Co New use
AUPP584198A0 (en) * 1998-09-14 1998-10-08 Fujisawa Pharmaceutical Co., Ltd. New use
WO2000023102A1 (en) 1998-10-19 2000-04-27 New York University Method for regulating the permeability of the blood brain barrier
US6864232B1 (en) * 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
EP1155021A1 (en) 1999-01-27 2001-11-21 Zielinski Laboratory Hesperitin pro-forms with enhanced bioavailability
AU775694B2 (en) * 1999-03-11 2004-08-12 Fujisawa Pharmaceutical Co., Ltd. Liposome preparations
HU228268B1 (en) * 1999-05-25 2013-02-28 Astellas Pharma Inc Method for separating analogous organic compounds
AUPQ078799A0 (en) * 1999-06-04 1999-06-24 Fujisawa Pharmaceutical Co., Ltd. New use
FI20000004A0 (fi) * 2000-01-03 2000-01-03 Slk Foundation Flavonoidilääke...
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
JP2004510694A (ja) * 2000-05-08 2004-04-08 ヘインズ　デイビッド 免疫抑制性組成物
FR2815033B1 (fr) * 2000-10-06 2003-09-05 Negma Lab Derives de 7-carboxy-flavones, porcede pour leur preparation et leur application en therapeutique
DE10056400A1 (de) * 2000-11-14 2002-05-23 Merck Patent Gmbh Galenische Formulierung
US20040091477A1 (en) * 2001-05-08 2004-05-13 David Haines Immunosuppresive compositions
ATE476178T1 (de) * 2001-09-06 2010-08-15 Synorx Inc Hemmung der t-lymphozyten-aktivierung durch 3- deoxyflavonoide und relevante therapien
US20040102386A1 (en) * 2001-09-06 2004-05-27 Thomas Lahey Inhibition by 3-deoxyflavonoids of T-lymphocyte activation and therapies related thereto
GB0125532D0 (en) 2001-10-24 2001-12-12 Burton Michael Enzyme activity indicators
HUP0402594A3 (en) * 2002-01-10 2006-01-30 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
US7169763B2 (en) * 2002-02-22 2007-01-30 Oliver Yoa-Pu Hu Cytochrome P450 3A inhibitors and enhancers
GB2391473B (en) * 2002-08-02 2004-07-07 Satishchandra Punambhai Patel Pharmaceutical compositions
GB2391471B (en) * 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
US20060100179A1 (en) * 2002-08-14 2006-05-11 Pero Ronald W Compositions and methods for use in targeting vascular destruction
US20050080021A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
US20050080024A1 (en) 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
DE10240923A1 (de) * 2002-09-02 2004-03-04 Merck Patent Gmbh Flavonoid-Derivate zur Ekzem-Behandlung
WO2004091540A2 (en) * 2003-04-15 2004-10-28 Theraquest Biosciences, Llc Methods of treating pain and compositions for use therefor
WO2004100868A2 (en) * 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
US20060124903A1 (en) * 2003-06-10 2006-06-15 Astellas Pharma Inc. Aerosol preparation comprising sealed container and enclosed therein aerosol composition containing marcolide compound
AU2004279644A1 (en) * 2003-10-10 2005-04-21 Resverlogix Corp. Treatment of diseases associated with the egr-1 enhancer element
DE102004002787A1 (de) 2004-01-19 2005-08-11 Merck Patent Gmbh Flavonoid-Komplexe
US7875650B2 (en) * 2004-02-03 2011-01-25 Yale University Compounds and methods to increase anti-P-glycoprotein activity of baicalein by alkylation on the A ring
CN1297552C (zh) 2004-03-11 2007-01-31 南京莱尔生物化工有限公司 木犀草素的合成方法
WO2006008092A1 (en) 2004-07-16 2006-01-26 Novartis Ag Use of a steroid for enhancement of skin permeability
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
EP1799228B1 (en) * 2004-09-14 2010-04-14 Ajinomoto Omnichem S.A. Topical compositions containing phosphorylated polyphenols
US20060069042A1 (en) * 2004-09-24 2006-03-30 Hu Oliver Y Cytochrome P450 2C9 inhibitors
CA2584485C (en) * 2004-10-20 2013-12-31 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US20070087977A1 (en) * 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
CN101080224B (zh) * 2004-11-16 2011-03-30 利默里克神经科学股份有限公司 治疗疼痛的组合物及其应用
NZ560633A (en) * 2005-03-11 2011-08-26 Neuprotect Pty Ltd Flavonoid compounds and uses thereof
WO2006119406A2 (en) 2005-05-03 2006-11-09 The Uab Research Foundation Compositions and methods for increasing osteoblast cell differentiation and bone generation
JP5368792B2 (ja) * 2005-07-29 2013-12-18 レスバーロジックス コーポレイション 複合疾患の予防および処置のための薬学的組成物および挿入可能な医療用デバイスによるその送達
WO2007084857A2 (en) 2006-01-13 2007-07-26 President And Fellows Of Harvard College Methods and compositions for treating cell proliferative disorders
JP2009532503A (ja) 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
GB0618168D0 (en) 2006-09-15 2006-10-25 Babraham Inst Compounds
WO2008080110A1 (en) * 2006-12-21 2008-07-03 Alcon, Inc. Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
EP2068865A4 (en) * 2006-12-28 2011-08-10 Limerick Biopharma Inc METHOD AND COMPOSITIONS FOR THERAPY TREATMENT
CA2693338A1 (en) 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Phosphorylated pyrone analogs and methods
WO2009018326A2 (en) 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Soluble pyrone analogs methods and compositions
US20090258939A1 (en) * 2007-07-31 2009-10-15 Wendye Robbins Pyrone analog compositions and methods
WO2009158031A2 (en) 2008-06-27 2009-12-30 Limerick Biopharma, Inc. Methods and compositions for therapeutic treatment
WO2009158007A2 (en) 2008-06-27 2009-12-30 Limerick Biopharma, Inc. Methods and compositions for therapeutic treatment
CA2740003A1 (en) * 2008-10-10 2010-04-15 Limerick Biopharma, Inc. Pyrone analogs for therapeutic treatment
US20100297020A1 (en) * 2008-10-10 2010-11-25 Limerick Biopharma, Inc. Phosphorylated and phosphonated pyrone analogs for therapeutic treatment
EP2424541A2 (en) 2009-04-27 2012-03-07 Limerick BioPharma, Inc. Phosphorylated and phosphonated pyrone analogs for therapeutic treatment

Also Published As

Publication number Publication date
ZA201001390B (en) 2011-05-25
GB2464645A (en) 2010-04-28
JP2011500512A (ja) 2011-01-06
MX2010001141A (es) 2010-03-01
EP2182957A2 (en) 2010-05-12
KR20100051829A (ko) 2010-05-18
US20100144612A1 (en) 2010-06-10
US7947733B2 (en) 2011-05-24
WO2009018338A2 (en) 2009-02-05
EP2182957A4 (en) 2012-07-18
US20100204089A1 (en) 2010-08-12
TW200924785A (en) 2009-06-16
GB201002044D0 (en) 2010-03-24
CA2693338A1 (en) 2009-02-05
AU2008282261A1 (en) 2009-02-05
WO2009018338A3 (en) 2010-11-11
US20090069273A1 (en) 2009-03-12
GB2464645B (en) 2010-11-24
CN101969959A (zh) 2011-02-09

Similar Documents

Publication Publication Date Title
BRPI0813647A2 (pt) Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados
BRPI0821573A2 (pt) benzofuropirimidonas
ATE501136T1 (de) Imidazopyridinone
DE502007001207D1 (de) Elektrosaugkopf
DK2159224T3 (da) Bromphenylsubstituerede thiazolyldihydropyrimidiner
ATE514696T1 (de) Diphenyl-dihydro-imidazopyridinone
DE602008002772D1 (de) Polyvinylpyrrolidonpulverzusammensetzungen
DE112008003636A5 (de) Mehrzuggruppierer
BRPI0811451A2 (pt) Exopolissacarídeo
DE602008000923D1 (de) Einzelwaferätzgerät
DE602008000749D1 (de) Buschschneider
BRPI0814519A2 (pt) Organopolissiloxano
BRPI0815547A2 (pt) Depsipeptídeos cícliocos
BRPI0812840A2 (pt) 2-imidazolinas
AT505058A3 (de) Türschliesssystem
DE602008001234D1 (de) Bandmaterialzuführvorrichtung
BRPI0812994A2 (pt) Microbiocidas
DE602008004695D1 (de) Katalysatorträgerwabe
BRPI0809678A2 (pt) Métodos
DE602008005589D1 (de) Rliganden
DE112008001216A5 (de) Magnetronplasmaanlage
DE502008001694D1 (de) Mitfahrhubwagen
DE112008003094A5 (de) Geomatte
DE112008003196A5 (de) Handpipettiergerät
DE602008000292D1 (de) Werkzeughaltepositioniervorrichtung

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]